Description
CPA.CE: Chlamydia Pneumoniae IgA – ELISA
Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgA antibodies to Chlamydia Pneumoniae in human plasma and sera. The product is intended for the follow-up of patients showing respiratory pathologies referable to Chl. Pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgA are captured, if present, by the solid phase. After washing out all the other components of the sample, in the 2nd incubation bound anti-CP IgA are detected by the addition of anti hIgA antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CP IgA antibodies present in the sample. The presence of IgA in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples. Neutralization of IgG anti-CP, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgA.
CPG.CE: Chlamydia Pneumoniae IgG – ELISA
Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies to Chlamydia pneumoniae in human plasma and sera. The kit is intended for the follow up of patients undergoing a Chlamydia pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgG are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-C.pneumoniae IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.pneumoniae IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.
CPM.CE: Chlamydia Pneumoniae IgM – ELISA
Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Chlamydia Pneumoniae in human plasma and sera. The product is intended for the follow-up of patients showing respiratory pathologies referable to Chl. pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgM are captured, if present, by the solid phase. After washing out all the other components of the sample, in the 2nd incubation bound anti-CP IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CP IgM antibodies present in the sample. The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples. Neutralization of IgG anti-CP, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.
